

Treatment of Asymptomatic Hyperuricemia in Chronic Kidney Disease: A New Target In An Old Enemy – A Review

Barse Priti Vinayak B¹ and Prof. More Ashwini B²

Student, Pratibhatai Pawar College of Pharmacy, Wadala Mahadev, Shrirampur¹

Assistant Professor, Pratibhatai Pawar College of Pharmacy, Wadala Mahadev, Shrirampur²

Corresponding Author: Barse Priti Vinayak

Abstract: Chronic kidney disease (CKD) is a severe condition and a significant public health issue worldwide, carrying the burden of an increased risk of cardiovascular events and mortality. The traditional factors that promote the onset and progression of Chronic kidney disease (CKD) are cardiometabolic risk factors like hypertension and diabetes, but non-traditional contributors are escalating. Hyperuricemia, i.e. increased serum uric acid (UA) concentration, is a common problem in clinical practice. While there are clear guidelines concerning management of symptomatic hyperuricemia in acute conditions such as gout, urolithiasis or acute urate nephropathy, less is known about their secondary prevention. Moreover, despite the ongoing debate on the role of Uric Acid (UA) in the pathogenesis of chronic kidney disease, hypertension, cardiovascular disease and heart failure, the management of asymptomatic hyperuricemia in patients with these chronic conditions is still mainly up to physicians' judgement. Individual considerations should always be taken into account when prescribing urate-lowering therapy. In this narrative review study, we attempt to present current trends concerning treatment of patients with either symptomatic or asymptomatic hyperuricemia in the light of the available knowledge on the role of hyperuricemia in the development of gout, renal, cardiovascular and other diseases.

Keywords: chronic kidney disease; hyperuricemia, uric acid

